ArticleDermato-endocrinology2010
Comorbidities of hidradenitis suppurativa (acne inversa).
Article in Dermato-endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 240 citations in OpenAlex.
- Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019Pooled it
- Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.JAMA dermatology · 2026Trial
- Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.International journal of dermatology · 2026Trial
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.JAMA dermatology · 2021Trial
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2016Trial
- Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities.The British journal of dermatology · 2014Trial
- Criteria for Hidradenitis Suppurativa Competence Centers.Dermatology and therapy · 2026Article
- Two-Stage Surgical Management of Anogenital Hidradenitis Suppurativa in Patients on Biologic Therapy: A Retrospective Case Series.International wound journal · 2026Article
- Dissecting Cellulitis of the Scalp: Linking Pathogenesis to Therapy.Biomedicines · 2026Review
- Exploring the Experience of Black Americans Living with Hidradenitis Suppurativa in the United States Healthcare System: A Narrative Review.Dermatology and therapy · 2025Review
- Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.Dermatology and therapy · 2025Review
- Ηidradenitis suppurativa associated with autoimmunity in children and adolescents; a case-based review.Rheumatology international · 2025Review
- Beyond the skin: endocrine, psychological and nutritional aspects in women with hidradenitis suppurativa.Journal of translational medicine · 2025Review
- Racial Differences in Disease Characteristics of Pediatric Hidradenitis Suppurativa.Pediatric dermatology · 2025Article
- Leveraging genotypes and phenotypes to implement precision medicine in hidradenitis suppurativa management.The British journal of dermatology · 2025Review
- Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be).Archives of dermatological research · 2025Article
- Analysis of the Efficacy and Safety of Secukinumab Combined with Surgical Treatment for Hidradenitis Suppurativa: A Real-World Retrospective Study in China.Journal of inflammation research · 2025Article
- Recurrence of Acne inversa of the penis - two-stage reconstruction with MatriDermGMS Interdisciplinary plastic and reconstructive surgery DGPW · 2025Article
- Investigating the association between hidradenitis suppurativa and malignancy risks: a systematic review.Archives of dermatological research · 2024Article
- Exploring the connection between hidradenitis suppurativa and erythema nodosum: a case report.Dermatology reports · 2024Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbidities of hidradenitis suppurativa (acne inversa) were reviewed by extracting original and review publications included in MEDLINE, EMBASE and COCHRANE libraries using the terms "hidradenitis," "Verneuil" and "acne inversa." Follicular occlusion disorders, inflammatory bowel diseases, especially Crohn disease, spondylarthropathy, other hyperergic diseases, genetic keratin disorders associated with follicular occlusion and squamous cell carcinoma were the most common hidradenitis suppurativa comorbid diseases. A first classification of these major comorbidities and their possible genetic background reveals a list of chromosome loci and genes, which could be hidradenitis suppurativa candidates. Most of these diseases belong to the group of autoinflammatory disorders, where th17 cell cytokines seem to play a central role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.